Technology

Benefits of Hydroxyl Dendrimer (HD) Therapeutics

Treat a broad range of diseases. 
With many known cellular pathways, it will be possible to design HDTs to alter the cells for the beneficial treatment of each disease

Target disease from systemic treatment (injection or oral) that cannot be targeted effectively by existing drug classes. 
Many small molecules and therapeutic proteins, including monoclonal antibodies, are not sufficiently selective or do not target only the diseased tissues. HDTs have been shown to selectively target reactive cells in diseased tissues

Increased potency and duration of action. 
Each HDT contains several drug molecules covalently conjugated to a single HD. As a result, one HDT can be very effective in altering one or more intracellular pathways. HDTs remain inside the target cells for up to one month providing a sustained localized effect without systemic exposure

Inexpensive to manufacture. 
Large scale (>1kg GMP lots) enable very competitive COGS and opens up new geographic market opportunities

Disease Cell-targeted Precision Medicine

Amplify the Benefit of Known Therapeutics by Eliminating Toxicity to Improve Patient Outcomes

Crosses Tissue Barriers

Systemic HDTs Target Reactive Cells in Diseased Tissue

Nance 2016; Zhang 2016

Simple, Elegant Physics Based Targeting

Endocytosis Rate >> Rate of Diffusion/Flow Past Cells in Region of Inflammation

Systemic HDTs Target Reactive Cells in Diseased Tissue

HDs Have All the Characteristics of an Ideal Targeted Drug Platform